Compare, Analyse Fresenius Kabi Onco. with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ACTAVIS (US) - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FRESENIUS KABI ONCO.   ACTAVIS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ACTAVIS
Dec-18
FRESENIUS KABI ONCO./
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs17613,746-   
Low Rs799,221-   
Sales per share (Unadj.) Rs37.73,371.9-  
Earnings per share (Unadj.) Rs5.1-1,086.1-  
Cash flow per share (Unadj.) Rs6.7355.3-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.513,907.7-  
Shares outstanding (eoy) m158.23332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.4 99.1%   
Avg P/E ratio x25.0-10.6 -236.3%  
P/CF ratio (eoy) x18.932.3 58.6%  
Price / Book Value ratio x3.00.8 362.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1353,819,451 0.5%   
No. of employees `0001.216.9 6.8%   
Total wages/salary Rs m7030-   
Avg. sales/employee Rs Th5,176.266,361.4 7.8%   
Avg. wages/employee Rs Th610.40-   
Avg. net profit/employee Rs Th699.6-21,375.1 -3.3%   
INCOME DATA
Net Sales Rs m5,9631,121,508 0.5%  
Other income Rs m1821,447 0.1%   
Total revenues Rs m5,9811,142,955 0.5%   
Gross profit Rs m1,43029,389 4.9%  
Depreciation Rs m258479,421 0.1%   
Interest Rs m-2664,717 -0.0%   
Profit before tax Rs m1,216-493,302 -0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68125,812 -0.1%   
Tax Rs m342-6,252 -5.5%   
Profit after tax Rs m806-361,238 -0.2%  
Gross profit margin %24.02.6 915.2%  
Effective tax rate %28.11.3 2,220.3%   
Net profit margin %13.5-32.2 -42.0%  
BALANCE SHEET DATA
Current assets Rs m5,102459,984 1.1%   
Current liabilities Rs m2,385406,917 0.6%   
Net working cap to sales %45.64.7 962.7%  
Current ratio x2.11.1 189.2%  
Inventory Days Days15020 766.1%  
Debtors Days Days11366 170.9%  
Net fixed assets Rs m5,148126,948 4.1%   
Share capital Rs m1580-   
"Free" reserves Rs m6,5560-   
Net worth Rs m6,7324,625,699 0.1%   
Long term debt Rs m9521,628,876 0.1%   
Total assets Rs m10,3887,231,020 0.1%  
Interest coverage x-45.8-6.6 691.2%   
Debt to equity ratio x0.10.4 40.2%  
Sales to assets ratio x0.60.2 370.1%   
Return on assets %7.5-4.1 -183.1%  
Return on equity %12.0-7.8 -153.3%  
Return on capital %14.6-4.8 -301.7%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,274400,673 0.3%  
From Investments Rs m-1,204220,117 -0.5%  
From Financial Activity Rs m-196-687,674 0.0%  
Net Cashflow Rs m-126-66,550 0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.04 Rs / USD

Compare FRESENIUS KABI ONCO. With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare FRESENIUS KABI ONCO. With: CIPLA  AJANTA PHARMA  SUVEN LIFESCIENCES  AUROBINDO PHARMA  FULFORD INDIA  



Today's Market

Key Q2FY20 Results, Global Stock Market Drivers, and Top Stocks in Action Today(Pre-Open)

On Monday, Indian share markets traded on a positive note most of the day and ended marginally higher. The BSE Sensex closed higher by 87 points to end the day at 38,214.

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks (Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS